What are the key supply-demand and regulatory factors shaping China's cefradine market outlook?

What are the key supply-demand and regulatory factors shaping China's cefradine market outlook?
China's cefradine market sits within a broader antibiotic API sector characterized by overcapacity, regional concentration of producers, and frequent price wars. Industry reports track cefradine output and pricing alongside other cephalosporins like cefazolin and cefuroxime, with 7-ADCA as a key upstream intermediate. Demand is driven by oral formulations for community-acquired infections, but faces headwinds from antimicrobial stewardship policies, including the 'limited antibiotic use' regulations that restrict hospital prescribing. The product's mature life cycle means low entry barriers but also intense competition among domestic API makers, many clustered in specific provinces. Export trends for cefradine are monitored separately, indicating some international trade exposure. Overall, growth is expected to be modest, with pricing pressured by overcapacity and substitution toward second-generation oral cephalosporins in clinical guidelines.